Theratechnologies (NASDAQ:THTX - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.08), Zacks reports. The business had revenue of $17,729 billion for the quarter, compared to analysts' expectations of $24.30 million.
Theratechnologies Stock Performance
Shares of NASDAQ THTX traded up $0.01 during trading on Thursday, reaching $3.15. The company had a trading volume of 409,125 shares, compared to its average volume of 890,821. Theratechnologies has a 52 week low of $1.12 and a 52 week high of $3.20. The stock has a market cap of $144.84 million, a PE ratio of -16.58 and a beta of 0.55. The business's 50 day moving average price is $2.63 and its 200-day moving average price is $2.10.
Hedge Funds Weigh In On Theratechnologies
A hedge fund recently raised its stake in Theratechnologies stock. Bank of America Corp DE increased its holdings in shares of Theratechnologies Inc. (NASDAQ:THTX - Free Report) by 1,416.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,487 shares of the company's stock after buying an additional 15,400 shares during the period. Bank of America Corp DE's holdings in Theratechnologies were worth $30,000 at the end of the most recent quarter.
Wall Street Analysts Forecast Growth
Separately, Jones Trading downgraded shares of Theratechnologies from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 3rd.
Check Out Our Latest Stock Report on THTX
About Theratechnologies
(
Get Free Report)
Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
See Also

Before you consider Theratechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theratechnologies wasn't on the list.
While Theratechnologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.